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Background: Non-small cell lung cancer (NSCLC) accounts for approximately 80% of new diagnoses of pulmonary
carcinoma. This study investigated the correlation between 18 F-fluorodeoxyglucose uptake in computerized
tomography integrated positron emission tomography and tumor size, lymph node metastasis, and distant
metastasis in patients with NSCLC.
Methods: The records of 151 NSCLC patients (139 male, 12 female; mean age 59.60 years) were evaluated
retrospectively.
Results: Forty-one cases were adenocarcinomas; 45 squamous cell carcinomas; and 65 unspecified NSCLC. When
the cases were categorized according to tumor size (group 1, ≤ 3 cm; group 2, > 3 and ≤ 5 cm; group 3, > 5 cm),
the maximum standardized uptake value (SUVmax) was significantly lower in groups 1 and 2 compared with group
3 (p = 0.006 for each). Considering all cases, tumor SUVmax was not correlated with age, gender, or
histopathological type. Lymph node metastases were pathologically proven in 24 cases: 24% of these were
adenocarcinomas, 6% squamous cell carcinomas, and 16% unspecified NSCLC. Neither lymph node involvement
nor distant metastases were correlated with tumor SUVmax, although lymph node size was positively correlated
with lymph node SUVmax (r = 0.775; p < 0.001).
Conclusions: SUVmax was significantly associated with tumor size, but not with distant metastases or lymph node
involvement. Therefore, SUVmax on positron emission tomography is not predictive of the presence of metastases.
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Pulmonary carcinoma is the most commonly diagnosed
cancer worldwide (1.61 million cases, 12.7% of total car-
cinomas) and is the most common cause of cancer death
(1.38 million deaths, 18.2% of total cancer deaths) [1].
Non-small cell lung cancer (NSCLC) accounts for ap-
proximately 80% of new pulmonary carcinoma diagnoses
and includes the histological subtypes adenocarcinoma,
squamous cell carcinoma, large cell undifferentiated car-
cinoma, and mixed histologies [2].
Recently, the uptake of 18 F-fluorodeoxyglucose (FDG) as
determined by computerized tomography integrated posi-
tron emission tomography (PET-CT) has become a widely* Correspondence: drekremcs@yahoo.com
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reproduction in any medium, provided the orused non-invasive diagnostic test. Fluorodeoxyglucose
PET-CT measures the standardized uptake value (SUV) of
a pulmonary mass, which quantifies the glucose avidity of
the tumor. Fluorodeoxyglucose PET-CT has been shown
to be useful for evaluating an indeterminate pulmonary
nodule, staging mediastinal lymph nodes, and evaluating
local nodal and distant metastases. Fluorodeoxyglucose
uptake correlates with the proliferative activity of tumor
and is an independent prognostic factor in patients with
lung cancer [3-6].
The objective of the present study is to assess whether
the maximum SUV (SUVmax) in PET-CT correlates
with tumor size, lymph node metastasis, distant metasta-
sis, and tumor histopathological type in patients with
NSCLC.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics and SUVmax of the NSCLC cases
n (%) SUVmax (mean ± SD)
Sex
Male 139 (92) 15.33 ± 6.87
Female 12 (8) 11.61 ± 3.66
Histology
Adenocarcinoma 41 (27) 15.14 ± 7.27
Squamous cell carcinoma 45 (30) 14.40 ± 5.39
Unspecified NSCLC 65 (43) 15.35 ± 7.27
Tumor size
≤ 3 cm 37 (25) 13.40 ± 6.57
> 3 ≤ 5 cm 69 (45) 13.98 ± 5.90
> 5 cm 45 (30) 17.91 ± 7.27
Lymph node metastases
N0 127 (84) 14.76 ± 6.72
N2 24 (16) 16.33 ± 9.02
Distant metastasis
M0 110 (73) 15.08 ± 6.80
M1 41 (27) 14.82 ± 6.62
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Study population
The records of 151 patients newly diagnosed with NSCLC
between November 2007 and November 2010 were eva-
luated retrospectively. The subjects were examined by
Fluorodeoxyglucose PET-CT and subsequently underwent
fiberoptic bronchoscopy for sampling of lymph nodes and
histological diagnosis of masses. A total of 139 males and
12 females were included in the study, with a mean age
59 ± 8.40 years (range 34–77 years). Pathologically, there
were 41 adenocarcinomas, 45 squamous cell carcinomas,
and 65 unspecified NSCLC.
Exclusion criteria were as follows: primary lesion
<1 cm, histology confirmed as other than NSCLC, type I
diabetes, prior history of lung cancer or other cancer
within the previous 5 years, previous therapy or surgical
staging for NSCLC before PET, massive or widespread
metastatic tumors such that the primary focus could not
be identified, and FDG-PET-CT scan performed more
than one month prior to tissue diagnosis.
FGD-PET-CT imaging
All patients underwent diagnostic and/or staging FDG-
PET-CT prior to biopsy or therapy. Patients were asked to
fast at least 6 h before the FDG-PET-CT scan. All patients
had a glucose level below 180 mg/dl and were injected
intravenously with 0.22 mCi (8.14 MBq)/kg (10–15 mCi/
370–555 MBq) FDG. At 60–90 min after the injection,
data were acquired from the vertex to the upper thigh.
The first CT scan was performed using 120 kV, 50 mA,
and a 3-mm section thickness. Immediately after CT, a
PET scan (Siemens Biograph; Siemens Medical Solutions,
Inc., Malvern, PA, USA) was performed for about 25 min,
with seven to eight bed positions and 3 min/position. PET
images were reconstructed iteratively with CT data for at-
tenuation correction, using an inline integrated Siemens
Esoft Workstation system. Computerized tomography in-
tegrated positron emission tomography fusion images in
transaxial, sagittal, and coronal planes were evaluated visu-
ally, and the SUVmax of lesions was obtained from
transaxial images.
Statistical evaluation
Statistical analysis was performed using SPSS software
(version 12.0). Values were expressed as means ± standard
deviation. Statistical significance was assessed at the p <
0.05 level. One-way analysis of variance was performed to
compare SUVmax among the histological types. Pearson’s
correlations were computed between tumor SUVmax and
tumor diameter, lymph node diameter, and lymph node
SUVmax. Independent samples t-test was used to deter-
mine the significance of the difference in tumor SUVmax
according to the presence of lymph node or distant
metastases.Results
The characteristics and SUVmax of the 151 NSCLC cases
are summarized in Table 1. A significant relationship was
found between tumor SUVmax and tumor size (r = 0.320;
p < 0.001). When the cases were divided into three groups
based on tumor size (group 1, ≤ 3 cm; group 2, >3 cm
and ≤ 5 cm; and group 3, >5 cm), tumor SUVmax did not
differ significantly between groups 1 and 2 (p > 0.05), while
it was significantly lower in groups 1 and 2 compared with
group 3 (p = 0.006 for each). Considering all cases, tumor
SUVmax was not significantly correlated with age, gender,
or histological type (adenocarcinoma, squamous cell car-
cinoma, and unspecified NSCLC).
Among the 151 cases, lymph node metastases were
pathologically proven in 24 cases (16%), all of which were
N stage 2 (ipsilateral mediastinal lymph node metastasis
with or without hilar or intrapulmonary lymph node me-
tastasis). Lymph node metastases were present in 24% (10/
41) of adenocarcinomas, 6% (3/45) of squamous cell car-
cinomas, and 16% (11/65) of unspecified NSCLC. When
cases were divided into two groups according to lymph
node involvement, there was no difference in tumor
SUVmax between the groups. However, lymph node size
was positively correlated with lymph node SUVmax (r =
0.775, p < 0.001). Tumor SUVmax did not differ signifi-
cantly according to the presence of distant metastases.
Discussion
Although CT or magnetic resonance imaging provides
precise anatomical and morphological information, the
role of FDG-PET-CT has increased for diagnosis and
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been reported to be a prognostic factor in patients with
lung cancer [4-6]. Patz et al. [8] demonstrated that pa-
tients with positive FDG-PET-CT results in treated lung
cancer had a significantly worse prognosis than patients
with negative results. Therefore, we examined whether
SUVmax correlates with tumor size, lymph node and
distant metastases in patients with NSCLC. Tumor size,
but not lymph node or distant metastases, was related to
the tumor SUVmax. Doom et al. [9] also reported a
strong significant association between tumor size and
SUVmax in patients with NSCLC. Another study in pa-
tients with stage I NSCLC showed a significant associ-
ation between the primary tumor, SUVmax and tumor
size, with tumors ≤ 3 cm having a significantly lower
SUV than tumors > 3 cm [10]. In addition, a retrospect-
ive analysis of 85 patients with solid pulmonary lesions
found a positive correlation between the size of a malig-
nant tumor and SUVmax [11]. A multivariate analysis
demonstrated that the combination of high SUV and
large lesion size identified a subgroup of patients with
the worst prognosis and a median survival rate of less
than 6 months [12].
Aquino et al. [13] reported a significant difference in
FDG uptake between the well-differentiated adenocarcin-
oma subtype bronchioloalveolar carcinoma (BAC) and
non-BAC adenocarcinomas, including well-differentiated
non-BAC tumors. Adenocarcinomas with mixed features
that included BAC had a peak SUV (1.5 ± 0.2) lower than
that of all other non-BAC adenocarcinomas (SUV, 3 ±
1.5), which included one poor tumor, three moderate tu-
mors, and one well-differentiated tumor [13]. Vesselle
et al. [2] showed that the uptake by large cell carcinomas
was greater than that by adenocarcinomas and was not
significantly different from uptake by squamous cell car-
cinomas. However, we observed no difference in SUVmax
among histological types. Our data were in concordance
with previous studies that documented lower uptake by
adenocarcinomas compared with squamous cell carcin-
omas [10,14-17] and lower uptake by BAC adenocarcin-
omas compared with non-BAC adenocarcinomas [18-20].
Fluorodeoxyglucose-PET-CT is already an indispens-
able modality for evaluating lymph node and distant
metastases. Many reports have suggested that FDG-PET-
CT is superior to CT in the accuracy of N-staging for
lung cancer [21-26]. Therefore, FDG-PET-CT is now
regarded as the most accurate imaging modality for
N-staging of lung cancer. However, a significant number
of false-negative and false-positive findings of lung can-
cer, including N-staging, on FDG-PET-CT have been
reported [27-31]. Nambu et al. [32] demonstrated that
the likelihood of lymph node metastasis increased with
an increase in SUVmax of the primary tumor; for pri-
mary lung cancer with a SUVmax greater than 12, theprobability of lymph node metastasis was high, reaching
70%, irrespective of the degree of FDG accumulation in
the lymph node stations. They concluded that this
finding would allow a more sensitive prediction of the
presence of lymph node metastases, including the mi-
croscopic ones that cannot be detected by direct eva-
luation of lymph node stations. Consistent with these
results, Higashi et al. [33] documented in a multicenter
study that the incidence of lymphatic vessel invasion and
lymph node metastasis in NSCLC were associated with
18 F-FDG uptake, concluding that 18 F-FDG uptake by
a primary tumor is a strong predictor of lymphatic vessel
invasion and lymph node metastasis. In the present
study, although tumor SUVmax was higher in patients
with lymph node metastasis than in those without, the
difference did not reach statistical significance. We also
observed that the frequency of lymph node metastasis
was higher in adenocarcinomas (24%) than in squamous
cell carcinomas (6%), suggesting that pathological sub-
type may be a significant factor associated with lymph
node metastasis. In contrast, a previous study showed
no difference in the frequency of lymph node metastasis
between the two pathological subtypes [32].
Based on univariate analysis, Jeong et al. [14] con-
cluded that metastasis detected by PET imaging, which
can affect staging by aiding in the discovery of metasta-
sis to contralateral lymph nodes or distant organs, was
an insignificant factor, and that metastatic findings
on PET had weak discriminative power. According to
Cerfolio et al. [16], FDG-PET-CT does not replace the
need for tissue biopsies for staging N1 or N2 lymph
nodes, or metastatic lesions, as false positives and false
negatives were observed in all stations in their study.
However, FDG-PET-CT resulted in better patient selec-
tion before pulmonary resection. FDG-PET can also help
in targeting areas for biopsy and identifying unsuspected
N2 and M1 disease [3]. In the present study, tumor
SUVmax was not significantly correlated with distant
metastases. This may be attributable to the finding of in-
creased 18 F-FDG uptake by subclinical inflammatory le-
sions as well as by malignant tumors.
Our study has limitations. As it is a retrospective
study, we can report only associations. In addition, we
elected to exclude diabetics and patients who received
chemotherapy, which might have caused a selection bias.
Conclusions
SUVmax was associated with tumor size, but not with
distant metastases or lymph node involvement. Thus,
SUVmax determined by FDG-PET-CT is not predictive
of the presence of metastases. Moreover, SUVmax was
not related to histological tumor. Larger prospective and
randomized analyses may potentially reveal more signifi-
cant relationships.
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